As self-funding continues to draw the attention of employers and benefits advisors, a number of questions, challenges and opportunities have arisen, leaving many employers and advisors uncertain about how and when to consider making a change. 

BenefitsPRO recently caught up with Josh McGee, Vice President of Program Development at Stealth Partner Group, an Amwins Group Company, to discuss the latest trends and strategies when it comes to self-funded plans and specific coverages like gene therapy. 

BenefitsPRO: Have there been any trends you’ve noticed in how self-insured employers have navigated the growing complexities of healthcare coverage like gene therapy?

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.